{"id":391683,"date":"2014-04-17T00:00:00","date_gmt":"2014-04-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/latron0414-biopharma-non-small-cell-lung-cancer-afatinib-gilotrif-wave-2-launchtrends-us-2014\/"},"modified":"2026-03-31T09:05:29","modified_gmt":"2026-03-31T09:05:29","slug":"latron0414-biopharma-non-small-cell-lung-cancer-afatinib-gilotrif-wave-2-launchtrends-us-2014","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/latron0414-biopharma-non-small-cell-lung-cancer-afatinib-gilotrif-wave-2-launchtrends-us-2014\/","title":{"rendered":"Non-Small-Cell Lung Cancer [Afatinib (Gilotrif) (Wave 2)] | LaunchTrends | US | 2014"},"content":{"rendered":"<p>LaunchTrends: Gilotrif is a series of three post-launch syndicated reports designed to track physician perception and uptake of newly launched Gilotrif (Boehringer Ingelheim\u2019s afatinib).<br \/>\nLaunchTrends: Gilotrif measures the impact of this novel agent on the metastatic non-small-cell lung cancer (NSCLC) market following launch. The study surveyed medical oncologists from the United States and conducted qualitative interviews with physicians. These reports evaluate physicians\u2019 current awareness and perception of Gilotrif relative to other currently available therapies for metastatic NSCLC, current and anticipated usage of Gilotrif, as well as promotional activity of Gilotrif.<\/p>\n","protected":false},"template":"","class_list":["post-391683","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-non-small-cell-lung-cancer","biopharma-therapy-areas-small-cell-lung-cancer","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391683\/revisions"}],"predecessor-version":[{"id":394806,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391683\/revisions\/394806"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}